Panel Discussion | Atherosclerosis Therapeutic Options and Management - What is Promising?

Sunday, March 9, 2025

11:43 AM - 12:05 PM ET

Panel Moderator(s)

Roxana Mehran, MD, FACC, FACP, FCCP, FESC, FAHA, MSCAI

Professor of Cardiology and Population Health Science and Policy, Mount Sinai Endowed Professor in Cardiovascular Clinical Research and Outcomes; Director of Interventional Cardiovascular Research and Clinical Trials; Director of Women’s Heart and Vascular Center at Mount Sinai Heart
Icahn School of Medicine at Mount Sinai, New York
New York, New York, United States

Disclosure information not submitted.
Charles German, MD, MS, FAHA, FASPC

Assistant Professor
Georgetown University

No relationships to disclose

Panel Discussant(s)

C. Michael Gibson, MD

Professor of Medicine
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States

No relationships to disclose
Paul A. Gurbel, MD, FSCAI

Director
Sinai Center for Thrombosis Research and Drug Development
Baltimore, Maryland, United States

Disclosure(s): No financial relationships to disclose
Elvin Kedhi, MD

Interventional Cardiologist Head of Innovation
Universite libre de Bruxelles
Westmount/ Montreal, Quebec, Canada

No relationships to disclose
Ramzi Khamis, MB ChB PhD FRCP FESC

Consultant Cardiologist. Clinical Director of Cardiology and Cardiothoracic Surgery
Imperial College London and Imperial College Healthcare NHS Trust
London , England, United Kingdom

No relationships to disclose
Michael Mahmoudi, MD

Professor of Interventional Cardiology
University Hospital Southampton NHS FT
Southampton, England, United Kingdom

No relationships to disclose
Nehal N. Mehta, MD, MSCE

Clinical Professor of Medicine
The George Washington University
Washington, District of Columbia, United States

Disclosure(s): No financial relationships to disclose
Robert S. Rosenson, MD

Director of Metabolism and Lipids
Mount Sinai Health System
New York, New York, United States

Disclosure information not submitted.
Scott W. Shurmur, MD

Chair, Internal Medicine; Interventional PD
Texas Tech Health Sciences Center, Lubbock
Lubbock, Texas, United States

No relationships to disclose
Jean-Claude Tardif, MD

Director of Research Center
Montreal Heart Institute
Montreal, Quebec, Canada

No relationships to disclose
Allen J. Taylor, MD

Chairman of Cardiology
MedStar Heart and Vascular Institute
Washington, District of Columbia, United States

No relationships to disclose

Disclosure(s):

Roxana Mehran, MD, FACC, FACP, FCCP, FESC, FAHA, MSCAI: Abbott, Alleviant Medical, Beth Israel Deaconess Medical Center, Concept Medical, Cordis, Elixir Medical, Faraday Pharmaceuticals, Idorsia Pharmaceuticals, Janssen, MedAlliance, Mediasphere Medical, Medtronic, Novartis, Protembis GmbH, Sanofi, RM Glo: Grant/Research Support (Ongoing); AMA - JAMA Cardiology (Associate Editor), ACC (BOT Member, SC Member CTR Program): Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Elixir Medical, Stel, ControlRad (spouse): Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Elixir Medical, IQVIA, Medtronic, Medscape/WebMD Global, NovoNordisk: Consultant (Ongoing), Consulting Fees (e.g., advisory boards) (Ongoing); SCAI (Women in Innovations Committee Member), Faculty Cardiovascular Research Foundation (CRF), Women as One (Founding Director): SCAI (Women in Innovations Committee Member), Faculty Cardiovascular Research Foundation (CRF), Women as One (Founding Director) (Ongoing)

Charles German, MD, MS, FAHA, FASPC: No financial relationships to disclose

C. Michael Gibson, MD: Amgen: Consulting Fees (e.g., advisory boards) (Ongoing); Angel Medical Systems, Inc.: Consultant (Ongoing); Bayer HealthCare: Consultant (Ongoing)

Paul A. Gurbel, MD, FSCAI: No financial relationships to disclose

Elvin Kedhi, MD: No financial relationships to disclose

Ramzi Khamis, MD PhD: No financial relationships to disclose

Michael Mahmoudi, MD: No financial relationships to disclose

Nehal N. Mehta, MD, MSCE: No financial relationships to disclose

Robert S. Rosenson, MD: Amgen Inc: Consulting Fees (e.g., advisory boards) (Ongoing); Arrowhead Pharmaceuticals, Inc.: Consulting Fees (e.g., advisory boards) (Ongoing); Avilar Therapeutics: Consulting Fees (e.g., advisory boards) (Ongoing); CRISPR Therapeutics: Consulting Fees (e.g., advisory boards) (Ongoing); Editas Medicine: Consulting Fees (e.g., advisory boards) (Ongoing); Eli Lilly and Company: Consulting Fees (e.g., advisory boards) (Ongoing); GSK: Consulting Fees (e.g., advisory boards) (Ongoing); Intercept Pharmaceuticals Inc: Consulting Fees (e.g., advisory boards) (Ongoing); Kowa American Corporation: Non-promotional lecture (Ongoing); Life Extension: Consulting Fees (e.g., advisory boards) (Ongoing); Lipigon Pharmaceuticals Inc.: Consulting Fees (e.g., advisory boards) (Ongoing); MediMergent LLC: Stock-privately held company (Ongoing); New Amsterdam: Consulting Fees (e.g., advisory boards) (Ongoing); Novartis: Consulting Fees (e.g., advisory boards) (Ongoing); Organon: Consulting Fees (e.g., advisory boards) (Ongoing); Precision BioSciences: Consulting Fees (e.g., advisory boards) (Ongoing); Regeneron Pharmaceuticals Inc.: Consulting Fees (e.g., advisory boards) (Ongoing); Rona Therapeutics, Inc.: Consulting Fees (e.g., advisory boards) (Ongoing); Ultragenyx Pharmaceuticals Inc.: Consulting Fees (e.g., advisory boards) (Ongoing); Verve: Consulting Fees (e.g., advisory boards) (Ongoing); Viatris: Non-promotional lecture (Ongoing); William Blair: Consulting Fees (e.g., advisory boards) (Ongoing); Wolters Kluwer: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)

Scott W. Shurmur, MD: No financial relationships to disclose

Jean-Claude Tardif, MD: Boehringer Ingelheim Pharmaceutical, Inc.: Grant/Research Support (Ongoing); Ceapro: Grant/Research Support (Ongoing); DalCor Pharmaceuticals: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Merck Pharmaceuticals: Grant/Research Support (Ongoing); Novartis Pharmaceuticals: Grant/Research Support (Ongoing); Pfizer,: Grant/Research Support (Ongoing); Verve Therapeutics: Grant/Research Support (Ongoing)

Allen J. Taylor, MD: Amgen: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Heartflow, Inc: Consultant (Ongoing)